PT  - JOURNAL ARTICLE
AU  - Yarnell, Christopher J
AU  - Barrett, Kali
AU  - Heath, Anna
AU  - Herridge, Margaret S.
AU  - Fowler, Rob
AU  - Sung, Lillian
AU  - Naimark, David M
AU  - Tomlinson, George
TI  - Costs, quality-adjusted life years, and value-of-information of different thresholds for the initiation of invasive ventilation in hypoxemic respiratory failure
AID  - 10.1101/2023.03.16.23286754
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.16.23286754
4099  - http://medrxiv.org/content/early/2023/03/16/2023.03.16.23286754.short
4100  - http://medrxiv.org/content/early/2023/03/16/2023.03.16.23286754.full
AB  - Objective To estimate costs, quality-adjusted life-years, and the value of undertaking a future randomized controlled trial for different oxygenation thresholds used to initiate invasive ventilation in hypoxemic respiratory failure.Design Model-based cost-utility estimation with individual-level simulation and value-of-information analysis.Setting Critical care units.Participants Adults admitted to critical care receiving non-invasive oxygen.Interventions We compared four strategies: initiation of invasive ventilation at thresholds of saturation-to-inspired oxygen fraction ratio (SF) < 110, < 98, or < 88, and usual care.Main results An invasive ventilation initiation threshold of SF < 110, compared to usual care, resulted in more predicted invasive ventilation (62% vs 31%), hospital survival (78.4% vs 75.5%), quality-adjusted life years (QALYs) (8.48 vs 8.34), and lifetime costs (86,700 Canadian dollars (CAD) vs 75,600 CAD). Among the four strategies, threshold SF < 110 had the highest expected net monetary benefit (761,000 CAD), but there was significant uncertainty, because all four strategies had similar probability (range: 23.5% to 27.5%) of having the best net monetary benefit. The expected value to society over the next 10 years of a 400-person randomized trial of oxygenation thresholds was 4.27 billion CAD, and remained high (2.64 billion CAD) in a scenario analysis considering a hypothetical threshold that resulted in less invasive ventilation and similar survival compared to usual care.Conclusion The preferred threshold to initiate invasive ventilation in hypoxemic respiratory failure is uncertain. It would be highly valuable to society to identify thresholds that, in comparison to usual care, either improve survival or reduce invasive ventilation without reducing survival.Question What are the costs and quality-adjusted life-years associated with different oxygenation thresholds for initiating invasive ventilation, and what is the expected value to society of a randomized controlled trial?Findings In this health economic evaluation comparing usual care to three different thresholds for initiating invasive ventilation in hypoxemic respiratory failure based on the saturation-to-inspired oxygen fraction ratio (SF), we found that threshold SF < 110 had the highest expected quality-adjusted life-years and net monetary benefit, despite increased predicted invasive ventilation use. However, there was significant residual uncertainty, and the expected value to society of a 400-person randomized trial to compare thresholds for initiating invasive ventilation was greater than 2.5 billion Canadian dollars.Meaning The preferred threshold to initiate invasive ventilation in hypoxemic respiratory failure is uncertain and further study would be valuable to society.Social media summary When should we intubate and start invasive ventilation for people with hypoxemic respiratory failure? Our health economic evaluation shows that the preferred threshold is uncertain, but that a clinical trial to determine such a threshold would be immensely valuable to patients and societyCompeting Interest StatementThe authors have declared no competing interest.Funding StatementDr Yarnell was funded by the Canadian Institutes for Health Research Vanier Scholar program, the Eliot Phillipson Clinician Scientist Training Program, and the Clinician Investigator Program of the University of Toronto. Dr Heath is supported by a Canada Research Chair in Statistical Trial Design and funded by the Discovery Grant Program of the Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03366). Dr Sung is supported by the Canada Research Chair in Pediatric Oncology Supportive Care. Dr Fowler is the H. Barrie Fairley Professor of Critical Care at the University Health Network, Interdepartmental Division of Critical Care Medicine, University of Toronto.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data for this study are either published in scientific journals or publicly available through Physionet (Medical Information Mart for Intensive Care version IV, https://physionet.org/content/mimiciv/2.2/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data for this study are either published in scientific journals or publicly available through Physionet (Medical Information Mart for Intensive Care version IV, https://physionet.org/content/mimiciv/2.2/). https://physionet.org/content/mimiciv/2.2/